QGEN vs. TEVA: Qiagen vs. Teva Pharmaceutical Stock Comparison

Company Profile

Qiagen (QGEN) and Teva Pharmaceutical (TEVA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but QGEN is classified in Life Sciences Tools & Services while TEVA is classified in Pharmaceuticals.

Qiagen (QGEN) trades as ordinary local shares, while Teva Pharmaceutical (TEVA) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Qiagen (QGEN) at 10.81% and Teva Pharmaceutical (TEVA) at 6.65% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Qiagen (QGEN) at 18.20% converts revenue to bottom-line profit above its industry’s benchmark range, while Teva Pharmaceutical (TEVA) at 2.94% keeps roughly the typical share for its industry.

Both Qiagen (QGEN) at 27.75% and Teva Pharmaceutical (TEVA) at 27.40% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Qiagen (QGEN) at 5.65% and Teva Pharmaceutical (TEVA) at 4.31% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Qiagen (QGEN) reports EPS growth of 409.76%, ranked against its industry; Teva Pharmaceutical (TEVA) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Qiagen (QGEN) at 2.63 keeps current ratio within its industry’s typical mid-range, while Teva Pharmaceutical (TEVA) at 0.95 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TEVA.

Qiagen (QGEN) at 0.47 is near its industry mid-range for debt-to-equity ratio, while Teva Pharmaceutical (TEVA) at 2.13 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Teva Pharmaceutical (TEVA) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Qiagen (QGEN) reports a yield of 0.71%, ranking against industry peers normally.

Teva Pharmaceutical (TEVA) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Qiagen (QGEN) reports a payout of 18.21%, ranking against industry peers normally.

Dividend Metrics

Valuation

Qiagen (QGEN) at 27.21 is near its industry’s usual P/E ratio, while Teva Pharmaceutical (TEVA) at 99.09 sits above its peer range — an unusually expensive price for TEVA’s trailing earnings.

Teva Pharmaceutical (TEVA) at 2.89 sits in the cheaper P/S ratio quartile while Qiagen (QGEN) at 4.91 prices around its industry’s middle — TEVA costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Qiagen (QGEN) at 2.99 and Teva Pharmaceutical (TEVA) at 6.23 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics